Compare AER & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AER | RVMD |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | Ireland | United States |
| Employees | N/A | 883 |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7B | 19.2B |
| IPO Year | 2006 | N/A |
| Metric | AER | RVMD |
|---|---|---|
| Price | $140.73 | $139.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $150.29 | $140.84 |
| AVG Volume (30 Days) | 1.1M | ★ 3.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.44 | $533.02 |
| P/E Ratio | $7.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $105.65 | $34.00 |
| 52 Week High | $154.94 | $155.70 |
| Indicator | AER | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 60.59 |
| Support Level | $140.42 | $93.39 |
| Resistance Level | $148.09 | $155.70 |
| Average True Range (ATR) | 4.03 | 7.75 |
| MACD | -0.36 | -0.59 |
| Stochastic Oscillator | 39.96 | 36.30 |
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. It has one business segment: leasing, financing, sales, and management of commercial flight equipment (Commercial Flight Equipment Segment). Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, the United States, and Other countries.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.